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Introduction
What’s new ?
Pancreatic ductal adenocarcinoma (PDAC) remains a deadly malignancy with no efficient therapy available
up-to-date. Thanks to a patented technology for mass spectrometry-assisted identification of accessible
tumor markers, developed in our laboratory, we have identified transforming growth factor-beta-induced
protein (TGFBI) as a targetable protein in pancreas adenocarcinoma. We focused our attention on its
biological significance in PDAC.
While PDAC continues to have exceedingly low 5-year survival rates, there is hope that
the discovery of reliable biomarkers and therapeutic targets can improve early diagnosis
and treatment outcomes. To that end, we identify the ECM TGFBI as a promising target.
In PDAC patients, high TGFBI expression was associated with poor outcome. Mechanistic
analyses show that TGFBI activates FAK signaling via integrin αVβ5 binding, enhancing
glycolysis and invasiveness in PDAC cells. olivier.peulen@uliege.be
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Fig 1: High TGFBI abundance is correlated to poor patient
outcome. FFPE samples (n=80) were stained for TGFBI.
Kaplan-Meier curve was constructed to assess disease
specific survival according to TGFBI abundance.
Fig 2: TGFBI depletion reduces migration and invasion of














Fig 3: rhTGFBI binds to ECM and to membrane proteins.





Fig 5: TGFBI enhances glycolysis in PDAC cell line.
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